Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer

Lung Cancer

Volumn 96, Issue , 2016, Pages 63-67

  Enomoto, Yasunori ^a   Inui, Naoki ^a   Kato, Terufumi ^b   Baba, Tomohisa ^b   Karayama, Masato ^a   Nakamura, Yutaro ^a   Ogura, Takashi ^b   Suda, Takafumi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

Author keywords

Forced vital capacity; Idiopathic pulmonary fibrosis; Interstitial lung diseases; Lung cancer; Risk factors

Indexed keywords

AMRUBICIN; CORTICOSTEROID; CYTOTOXIC AGENT; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; TOPOTECAN; ANTINEOPLASTIC AGENT;

ACUTE EXACERBATION OF PREEXISTING INTERSTITIAL LUNG DISEASE; ADULT; AGED; ALLERGIC PNEUMONITIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG PULSE THERAPY; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENERAL CONDITION DETERIORATION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PNEUMOCONIOSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; LUNG TUMOR; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; SMOKING; VERY ELDERLY; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84962439872     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.03.017     Document Type: Article

References (17)

1. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183:788-824.
2. Tomassetti S., Gurioli C., Ryu J.H., Decker P.A., Ravaglia C., Tantalocco P., et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015, 147:157-164.
3. Minegishi Y., Kokuho N., Miura Y., Matsumoto M., Miyanaga A., Noro R., et al. Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. Lung Cancer 2014, 85:258-263.
4. Kudoh S., Kato H., Nishiwaki Y., Fukuoka M., Nakata K., Ichinose Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am. J. Respir. Crit. Care Med. 2008, 177:1348-1357.
5. Takeda A., Enomoto T., Sanuki N., Nakajima T., Takeda T., Sayama K., et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat. Med. 2008, 26:504-507.
6. Kenmotsu H., Naito T., Kimura M., Ono A., Shukuya T., Nakamura Y., et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J. Thorac. Oncol. 2011, 6:1242-1246.
7. Minegishi Y., Takenaka K., Mizutani H., Sudoh J., Noro R., Okano T., et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern. Med. 2009, 48:665-672.
8. Song J.W., Hong S.B., Lim C.M., Koh Y., Kim D.S. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J. 2011, 37:356-363.
9. Collard H.R., Moore B.B., Flaherty K.R., Brown K.K., Kaner R.J., King T.E., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2007, 176:636-643.
10. Kondoh Y., Taniguchi H., Katsuta T., Kataoka K., Kimura T., Nishiyama O. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2010, 27:103-110.
11. Mura M., Porretta M.A., Bargagli E., Sergiacomi G., Zompatori M., Sverzellati N., et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur. Respir. J. 2012, 40:101-109.
12. Judge E.P., Fabre A., Adamali H.I., Egan J.J. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur. Respir. J. 2012, 40:93-100.
13. Tamiya A., Naito T., Miura S., Morii S., Tsuya A., Nakamura Y., et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res. 2012, 32:1103-1106.
14. Watanabe N., Niho S., Kirita K., Umemura S., Matsumoto S., Yoh K., et al. Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother. Pharmacol. 2015, 76:69-74.
15. Minegishi Y., Kuribayashi H., Kitamura K., Mizutani H., Kosaihira S., Okano T., et al. The feasibility study of carboplatin plus etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. J. Thorac. Oncol. 2011, 6:801-807.
16. Enomoto Y., Kenmotsu H., Watanabe N., Baba T., Murakami H., Yoh K., et al. Efficacy and safety of combined carboplatin, paclitaxel, and bevacizumab for patients with advanced non-squamous non-small cell lung cancer with pre-existing interstitial lung disease: a retrospective multi-institutional study. Anticancer Res. 2015, 35:4259-4263.
17. Enomoto Y., Inui N., Imokawa S., Karayama M., Hasegawa H., Ozawa Y., et al. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Cancer Chemother. Pharmacol. 2015, 76:499-505.